In addition, this treatment may be excessive as some patients progress to geographic atrophy in the posterior pole and macular area, perhaps because VEGF proteins are associated with cell survival [4–7] and repetitive anti-VEGF injections may reduce the VEGF levels required for cell health. The gene discussed is VEGFA; the disease is atrophic macular degeneration.